Hainan Sinotau In-Licenses Radiopharmaceutical from Navidea of the US

Hainan Sinotau Pharma and Navidea Biopharma of the US struck a deal under which Sinotau will have rights to develop and commercialize Lymphoseek® Injection in China. Lymphoseek is a radiopharmaceutical developed by Navidea to detect lymph nodes in patients with breast cancer or melanoma. Sinotau will be responsible for obtaining China approval of Lymphoseek. It will also be liable for up to $2.5 million in milestones, including a $300,000 upfront payment, along with payments based on unit sales and a royalty on sales. More details.... Stock Symbol: (NYSE: NAVB) Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.